Toll-like receptor 2 signaling modulates the functions of CD4+CD25+ regulatory T cells

被引:394
|
作者
Liu, HY [1 ]
Komai-Koma, M [1 ]
Xu, D [1 ]
Liew, FY [1 ]
机构
[1] Univ Glasgow, Div Immunol Infect & Inflammat, Glasgow G11 6NT, Lanark, Scotland
基金
英国惠康基金; 英国医学研究理事会;
关键词
colitis; Pam3CSK; Foxp3; Leishmania;
D O I
10.1073/pnas.0601554103
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Toll-like receptors (TLRs) are primary sensors of both innate and adaptive immune systems and play a pivotal role in response against structurally conserved components of pathogens. Synthetic bacterial lipoprotein (BLP) Pam3Cys-SK4 is a TLR2 agonist that is capable of modulating T cell immune responses. We show here that BLP, together with anti-CD3 antibody [T cell receptor (TcR) activation], induced proliferation of both CD4(+)CD25(+) regulatory T cells (Tregs) and CD4(+)CD25(-) (effector) T cells in the absence of antigen-presenting cells. The expanded Tregs showed a transient loss of suppressive activity. Moreover, BLIP rendered effectors resistant to the suppression of Tregs by increasing IL-2 secretion. BLP also transiently suppressed the induction of Foxp3 (X-linked forkhead/winged helix transcription factor) mRNA in Tregs at the first 8-15 h after T cell receptor activation. Consistent with this observation, BLP-stimulated Tregs regained their inhibitory activity and prevented spontaneous colitis induced by effectors in severe combined immunodeficient mice. Our results demonstrate a previously unrecognized pathway by which TLR expressed on T cells may directly modulate the immune response. Thus, during an acute bacterial infection, BLIP may rapidly increase the host's adaptive immunity by expanding effectors and also by attenuating the suppressive activity of Tregs. In the process, BLP also expands the Tregs, which recover their suppressive activity when the infection has subsided, in time to limit potential auto-immunity that might result from the overactivated effectors.
引用
收藏
页码:7048 / 7053
页数:6
相关论文
共 50 条
  • [31] CD4+CD25+ regulatory T-cells in the septic patient
    Monneret, Guillaume
    Venet, Fabienne
    Pachot, Alexandre
    Bohe, Julien
    Lepape, Alain
    INFLAMMATION RESEARCH, 2007, 56 : S127 - S127
  • [32] Isolation of CD4+CD25+ regulatory T cells for clinical trials
    Hoffmann, P
    Boeld, TJ
    Eder, R
    Albrecht, J
    Doser, K
    Pieshka, B
    Dada, A
    Niemand, C
    Assenmacher, M
    Orsó, E
    Andreesen, R
    Holler, E
    Edinger, M
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2006, 12 (03) : 267 - 274
  • [33] Prevention of autoimmune disease by CD4+CD25+ regulatory T cells
    Van Driel, IR
    Zwar, TD
    Allen, S
    Read, S
    Gleeson, PA
    TISSUE ANTIGENS, 2005, 66 (05): : 574 - 575
  • [34] The effects of antibody treatment on regulatory CD4+CD25+ T cells
    Yi, Huanfa
    Zhang, Jialin
    Zhao, Yong
    TRANSPLANT IMMUNOLOGY, 2008, 19 (01) : 37 - 44
  • [35] CD4+CD25+ regulatory T cells in human lupus erythematosus
    Annegret Kuhn
    Stefan Beissert
    Peter H. Krammer
    Archives of Dermatological Research, 2009, 301 : 71 - 81
  • [36] CD4+CD25+ regulatory T cells in human lupus erythematosus
    Kuhn, Annegret
    Beissert, Stefan
    Krammer, Peter H.
    ARCHIVES OF DERMATOLOGICAL RESEARCH, 2009, 301 (01) : 71 - 81
  • [37] CD4+CD25+ regulatory T cells in rheumatoid arthritis.
    van Amelsfort, JMR
    Jacobs, KMG
    Bijlsma, JWJ
    Lafeber, FPJ
    Taams, LS
    ARTHRITIS AND RHEUMATISM, 2002, 46 (09): : S486 - S486
  • [38] Role of CD4+CD25+ regulatory T cells in corneal neovascularization
    Usui, T
    Yamagami, S
    Kishimoto, S
    Mimura, T
    Ono, K
    Yokoo, S
    Amano, S
    Ishida, S
    Usui, Y
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2005, 46
  • [39] The role of CD4+CD25+ regulatory T cells in viral infections
    Vahlenkamp, TW
    Tompkins, MB
    Tompkins, WAF
    VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, 2005, 108 (1-2) : 219 - 225
  • [40] The role of CD4+CD25+ regulatory T cells in Leishmania infection
    Belkaid, Y
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2003, 3 (06) : 875 - 885